Interaction of a cyclic peptide, Ro09-0198, with phosphatidylethanolamine in liposomal membranes.
Ro09-0198 is a cyclic peptide isolated from Streptoverticillium griseoverticillatum. This peptide caused permeability increase and aggregation of liposomes containing phosphatidylethanolamine. Liposomes containing phosphatidylserine, phosphatidylinositol or cardiolipin instead of phosphatidylethanolamine were, however, not appreciably reactive with the peptide. Among the structural analogs of phosphatidylethanolamine, dialkylphosphatidylethanolamine and 1-acylglycerophosphoethanolamine incorporated into liposomes could interact with Ro09-0198 to cause a permeability increase, whereas liposomes consisting of alkylphosphoethanolamine or phosphatidyl-N-monomethylethanolamine were insensitive to the peptide. These findings indicate that a glycerol backbone and a primary amino group of phosphatidylethanolamine are necessary for interaction with Ro09-0198 to cause membrane damage. Ro09-0198 induced a selective permeability change on liposomes. Glucose and umbelliferyl phosphate were effluxed significantly, but sucrose was only slightly permeable and inulin could not be released. Consequently, the permeability increase induced by Ro09-0198 is rather specific to molecules smaller than sucrose. Line broadening of electron spin resonance signals of spin-labeled phosphatidylethanolamine was observed upon treatment of liposomes with Ro09-0198. It was suggested from these results that Ro09-0198 can alter the physical organization of phosphatidylethanolamine in membranes, thus providing a basis for changes in membrane permeability.
Choung
S Y
SY
Department of Health Chemistry, Faculty of Pharmaceutical Sciences, University of Tokyo, Japan.
Kobayashi
T
T
Takemoto
K
K
Ishitsuka
H
H
Inoue
K
K
D000192:Actinomycetales / Q000378:metabolism; D000900:Anti-Bacterial Agents; D004578:Electron Spin Resonance Spectroscopy; D005947:Glucose / Q000378:metabolism; D006460:Hemolysin Proteins / Q000494:pharmacology*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D008081:Liposomes / Q000378:metabolism*; D009943:Organophosphorus Compounds / Q000378:metabolism; D010455:Peptides; D010456:Peptides, Cyclic / Q000494:pharmacology*; D010539:Permeability; D010714:Phosphatidylethanolamines / Q000378:metabolism* / Q000494:pharmacology; D010742:Phospholipid Ethers / Q000378:metabolism / Q000494:pharmacology; D013053:Spectrophotometry; D013329:Structure-Activity Relationship; D013395:Sucrose / Q000378:metabolism; D014468:Umbelliferones / Q000378:metabolism
D000900:Anti-Bacterial Agents; D006460:Hemolysin Proteins; D008081:Liposomes; D009943:Organophosphorus Compounds; D010455:Peptides; D010456:Peptides, Cyclic; D010714:Phosphatidylethanolamines; D010742:Phospholipid Ethers; D014468:Umbelliferones; C055997:umbelliferyl phosphate; C055996:lanthiopeptin; D013395:Sucrose; D005947:Glucose